Loading...
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
BACKGROUND: Cabazitaxel, a semisynthetic microtubule inhibitor, has shown antitumour activity in models resistant to paclitaxel and docetaxel, and it has been approved for the treatment of docetaxel-resistant prostate cancer. We investigated its activity in patients with advanced non-small-cell lung...
Saved in:
| Published in: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5046219/ https://ncbi.nlm.nih.gov/pubmed/27607471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|